- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Granules India’s wholly-owned US subsidiary underwent a US FDA Pre-Approval Inspection for its first-to-file controlled substance ANDA at its Chantilly, Virginia facility, receiving one observation. The company has addressed and resolved this observation during the inspection, indicating readiness for product approval and potential market launch ahead. This development could strengthen Granules’ US footprint and revenue from controlled substance generics.